CancerDrs

Head and Neck Cancer clinical trials in Texas

97 actively recruiting head and neck cancer trials at 28 sites across Texas.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 2, Phase 3 Recruiting Academic/Other

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy s…

Sponsor: NRG Oncology
NCT ID: NCT04333537
Sites in Texas:
  • MD Anderson in The Woodlands — Conroe, Texas
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center — Houston, Texas
  • M D Anderson Cancer Center — Houston, Texas
  • Michael E DeBakey VA Medical Center — Houston, Texas
  • MD Anderson West Houston — Houston, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor recept…

Sponsor: AstraZeneca
NCT ID: NCT07431281
Sites in Texas:
  • Research Site — Dallas, Texas
  • Research Site — Sherman, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.

Sponsor: Merus B.V.
NCT ID: NCT06496178
Sites in Texas:
  • Site 55 — Denison, Texas
  • Site 34 — El Paso, Texas
  • Site 51 — Houston, Texas
  • Site 7 — Houston, Texas
  • Site 94 — Pearland, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refract…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07276399
Sites in Texas:
  • UT Southwestern Medical Center — Dallas, Texas
  • Texas Oncology - San Antonio — Fredericksburg, Texas
  • MD Anderson Cancer Center — Houston, Texas
  • Texas Oncology-Central South — Waco, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is …

Sponsor: AVEO Pharmaceuticals, Inc.
NCT ID: NCT06064877
Sites in Texas:
  • MD Anderson Cancer Center — Houston, Texas
  • Oncology Consultants — Houston, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer

This study is being done to answer the following question: Is the chance of cancer spreading or returning the same if radiotherapy to the neck is guided, by using a special imaging study called lymph node mapping (lymphatic mapping) Single…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT05451004
Sites in Texas:
  • MD Anderson in The Woodlands — Conroe, Texas
  • M D Anderson Cancer Center — Houston, Texas
  • MD Anderson West Houston — Houston, Texas
  • MD Anderson League City — League City, Texas
  • MD Anderson in Sugar Land — Sugar Land, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases

The goal of this clinical trial is to learn if ASP-1929 photoimmunotherapy (PIT) in combination with pembrolizumab works to treat recurrent squamous cell cancer of the head and neck (HNSCC) with no distant metastases. It will also learn ab…

Sponsor: Rakuten Medical, Inc.
NCT ID: NCT06699212
Sites in Texas:
  • University of Texas, MD Anderson Cancer Center — Houston, Texas
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-ra…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT02734537
Sites in Texas:
  • Saint Joseph Regional Cancer Center — Bryan, Texas
  • MD Anderson in The Woodlands — Conroe, Texas
  • Parkland Memorial Hospital — Dallas, Texas
  • UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
  • University of Texas Medical Branch — Galveston, Texas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…

Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in Texas:
  • UT Southwestern Medical Center — Dallas, Texas
  • Local Institution - 2127 — Houston, Texas
  • MD Anderson Cancer Center — Houston, Texas
  • Local Institution - 2146 — Kingwood, Texas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…

Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Texas:
  • New Experimental Therapeutics - NEXT Oncology — Austin, Texas
  • UTSW - Moody Outpatient Center - Parkland Health — Dallas, Texas
  • UT Southwest Simmons Cancer Center — Dallas, Texas
  • The University of Texas MD Anderson Cancer Center — Houston, Texas
  • New Experimental Therapeutics of San Antonio - NEXT Oncology — San Antonio, Texas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with…

Sponsor: Eli Lilly and Company
NCT ID: NCT05768139
Sites in Texas:
  • Mary Crowley Cancer Research Center — Dallas, Texas
  • Texas Oncology-Baylor Charles A. Sammons Cancer Center — Dallas, Texas
  • University of Texas Southwestern — Dallas, Texas
  • University of Texas MD Anderson Cancer Center — Houston, Texas
  • START San Antonio — San Antonio, Texas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.

Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in Texas:
  • Mary Crowley Cancer Research — Dallas, Texas
  • MD Anderson — Houston, Texas
  • NEXT Dallas — Irving, Texas
  • NEXT Oncology San Antonio — San Antonio, Texas
  • START Texas — San Antonio, Texas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-ri…

Sponsor: Marengo Therapeutics, Inc.
NCT ID: NCT05592626
Sites in Texas:
  • The University of Texas, MD Anderson Cancer Center — Houston, Texas
  • UT Health Mays Cancer Center — San Antonio, Texas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a monotherapy…

Sponsor: Avenzo Therapeutics, Inc.
NCT ID: NCT07038343
Sites in Texas:
  • Avenzo Therapeutics Recruiting Site — Dallas, Texas
  • Avenzo Therapeutics Recruiting Site — Houston, Texas
  • Avenzo Therapeutics Recruiting Site — San Antonio, Texas
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ …

Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06695845
Sites in Texas:
  • Texas Oncology - West Texas — Amarillo, Texas
  • Texas Oncology - DFW — Dallas, Texas
  • MD Anderson Cancer Center — Houston, Texas
  • Texas Oncology - San Antonio — San Antonio, Texas
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer

The purpose of this study is to determine if RRx-001, which is added on to the cisplatin and radiation treatment, reduces the incidence of severe oral mucositis in patients with head and neck cancers. All patients in this study will receiv…

Sponsor: EpicentRx, Inc.
NCT ID: NCT05966194
Sites in Texas:
  • University of Texas Southwestern Medical Center — Dallas, Texas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to avai…

Sponsor: VM Oncology, LLC
NCT ID: NCT03556228
Sites in Texas:
  • The University of Texas MD Anderson Cancer Center (site 127) — Houston, Texas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.

Sponsor: GV20 Therapeutics
NCT ID: NCT05669430
Sites in Texas:
  • Oncology Consultants, P.A. — Houston, Texas
  • The University of Texas M. D. Anderson Cancer Center — Houston, Texas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab or docetaxel in participants with advanced solid tumors. This study is a first-in-human…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT04895709
Sites in Texas:
  • Houston Methodist Hospital — Houston, Texas
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it…

Sponsor: Bayer
NCT ID: NCT06760819
Sites in Texas:
  • The University of Texas MD Anderson Cancer Center - Texas Medical Center — Houston, Texas
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

DESTINY-Gastric03 will investigate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of trastuzumab deruxtecan (T-DXd) alone or in combination with chemotherapy and/or immunotherapy in HER2-expr…

Sponsor: AstraZeneca
NCT ID: NCT04379596
Sites in Texas:
  • Research Site — Houston, Texas
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab compared against cemiplimab combined with placebo (a placebo looks like a treatment but does not contain a…

Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06769698
Sites in Texas:
  • Joe Arrington Cancer Research & Treatment Center — Lubbock, Texas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

This is a phase 1/2 multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of sacituzumab tirumotecan (MK-2870) plus paclitaxel versus ramucirumab plus paclitaxel, and HER3-DXD plus ramucirumab versus ra…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06445972
Sites in Texas:
  • University of Texas MD Anderson Cancer Center ( Site 8920) — Houston, Texas
View on ClinicalTrials.gov →

Showing 25 of 97 trials with sites in Texas. See all head and neck cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-05-25